Patent application number | Description | Published |
20120005667 | INTEGRATED EXCHANGE OF DEVELOPMENT TOOL CONSOLE DATA - Embodiments of the present invention provide a method, system and computer program product for exchanging console data in a messaging system. In an embodiment of the invention, a method for exchanging console data in a messaging system includes receiving a message in a messaging client executing in memory by at least one processor of a computer. The method further includes selecting in the message in the messaging client a portion of console data for a version of source code. For instance, the console data can be a selection of source code or an error message for a selection of source code. Finally, in response to the selection of the portion of console data, corresponding meta-data for the message can be extracted and a version of source code for the console data can be determined from the meta-data. Finally, the version of the source code can be loaded in an IDE executing in the memory by the at least one processor of the computer. | 01-05-2012 |
20140089897 | INTEGRATED EXCHANGE OF DEVELOPMENT TOOL CONSOLE DATA - Embodiments of the present invention provide a method, system and computer program product for exchanging console data in a messaging system. In an embodiment of the invention, a method for exchanging console data in a messaging system includes receiving a message in a messaging client executing in memory by at least one processor of a computer. The method further includes selecting in the message in the messaging client a portion of console data for a version of source code. For instance, the console data can be a selection of source code or an error message for a selection of source code. Finally, in response to the selection of the portion of console data, corresponding meta-data for the message can be extracted and a version of source code for the console data can be determined from the meta-data. Finally, the version of the source code can be loaded in an IDE executing in the memory by the at least one processor of the computer. | 03-27-2014 |
Patent application number | Description | Published |
20090105125 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 04-23-2009 |
20100047225 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 02-25-2010 |
20140348832 | INHIBITORS OF T-CELL ACTIVATION - The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex. | 11-27-2014 |
20150050262 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF - The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. | 02-19-2015 |
20150051261 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 02-19-2015 |
Patent application number | Description | Published |
20110110567 | Methods and Apparatus for Visually Enhancing Images - The invention provides methods of enhancing tissue sample images by filtering luminance values from an input image and transforming the filtered values to produce an enhanced image for use in diagnostic applications. Preferred methods of the invention provide image enhancement by filtering luminance values of an image that correspond to sample regions that are obstructed or are otherwise not of diagnostic interest, and applying a mathematical transformation based on luminance values from regions that are not filtered out. In this way, image correction is substantially based on portions of the image that are of diagnostic relevance. | 05-12-2011 |
20110144462 | MINIATURIZED MULTI-SPECTRAL IMAGER FOR REAL-TIME TISSUE OXYGENATION MEASUREMENT - A portable multi-spectral imaging system and device is disclosed. The system includes at least one image acquisition device for acquiring an image from a subject, a filtering device to filter the light received by the image acquisition device, a processor for processing the image acquired by the image acquisition device, and a display. There is software running on the processor that determines oxygenation values of the subject based on the processed image. | 06-16-2011 |
20140154703 | CIRCULATING TUMOR CELL CAPTURE ON A MICROFLUIDIC CHIP INCORPORATING BOTH AFFINITY AND SIZE - The invention encompasses methods and devices for diagnosing, theranosing, or prognosing a condition in a patient by enriching a sample in rare cells or other particles. The devices can be a microfluidic device comprising an array of obstacles and one or more binding moieties. The devices and methods can allow for enrichment of cells based on size and affinity, recovery of cells or other particles in locations on the microfluidic device, release of cells or other particles from the microfluidic device, flow of sample through the microfluidic device, and retention of rare cells or other particles from a sample obtained from a patient having a condition. | 06-05-2014 |
Patent application number | Description | Published |
20120027743 | Method for the Treatment of Hemophilia - The present invention is directed to a method for the treatment of hemophilia. | 02-02-2012 |
20130017997 | Factor VIII Compositions and Methods of Making and Using Same - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 01-17-2013 |
20130108629 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof | 05-02-2013 |
20130171175 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 07-04-2013 |
20130202595 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 08-08-2013 |
20130274194 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof - The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 10-17-2013 |
20140294821 | FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF - The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells | 10-02-2014 |
20140370035 | METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY - The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain. | 12-18-2014 |
20150023959 | CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF - The present invention provides a VWF fragment comprising the D′ domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins. | 01-22-2015 |
20150038421 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 02-05-2015 |
20150079072 | Assays to Monitor Bleeding Disorders - The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample | 03-19-2015 |
20150158929 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 06-11-2015 |
20150252345 | Methods of Using FIX Polypeptides - The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells. | 09-10-2015 |
20150266944 | Methods of Using FVIII Polypeptide - The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting Factor VIII polypeptide. The long-acting FVIII polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia. The present invention relates generally to the field of therapeutics for hemostatic disorders. | 09-24-2015 |
Patent application number | Description | Published |
20110250604 | METHODS OF DETECTING SOURCES OF MICROORGANISM CONTAMINATION - Methods of detecting a source of a microbial contamination in a suspect sample include detecting at least one member selected from the group consisting of a microbial geosmin synthase, a microbial 2-methylisoborneol synthase and a microbial 2-methylgeranyl diphosphate synthase in the suspect sample. The method can include conducting a nucleic acid amplification assay in the presence of at least one member selected from the group consisting of at least one microbial geosmin primer and at least one microbial 2-methylisoborneol synthase primer on a sample obtained from a suspect source of the microbial contamination. | 10-13-2011 |
20140163079 | DIPHOSPHATE MIMETICS AND USES THEREOF - The present invention provides compounds of Formulae (I)-(V), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In one aspect, compounds of the present invention are useful as glycosyltransferase inhibitors, in particular, O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) inhibitors. In another aspect, compounds of the present invention are useful as kinase inhibitors, in particular, PLK1 inhibitors, GSK3P inhibitors, or MAPKAPK2 inhibitors. The present invention further provides methods of using the inventive compounds, e.g., as biological probes to study the inhibition of OGT and/or kinase activity and as therapeutics, e.g., for the treatment of OGT-associated and/or kinase-associated conditions. | 06-12-2014 |
Patent application number | Description | Published |
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
20130157258 | HCV NS5B PROTEASE MUTANTS - The invention provides polypeptides comprising an amino acid sequence comprising at least one variation from wild-type HCV NS5B polymerase, the at least one variation selected from the group consisting of cysteine, isoleucine, valine, or proline at amino acid position 419; alanine, valine, or asparagine at amino acid position 482; valine, isoleucine, threonine, or serine at amino acid position 486; and isoleucine at amino acid position 494, as the amino acid positions are defined in SEQ ID NO: 1, and having Hepatitis C Virus (HCV) NS5B polymerase activity. Polynucleotides encoding the polypeptide, antibodies, host cells, compositions, and methods for detecting an HCV NS5B polymerase having resistance to a polymerase inhibitor also are provided. | 06-20-2013 |
20130252920 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG - Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents. | 09-26-2013 |
20140142119 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 05-22-2014 |
20140296201 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 10-02-2014 |
Patent application number | Description | Published |
20080305557 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus. | 12-11-2008 |
20090029349 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus. | 01-29-2009 |
20090318627 | SOLID PHASE SYNTHESIS OF ACRIDINIUM DERIVATIVES - Acridinium-functionalized solid-phase supports and methods for making acridinium-functionalized solid-phase supports are disclosed. The acridinium-functionalized solid-phase supports comprise a solid phase support linked to a chemiluminescent substituted acridinium compound through a linker group covalently attached to the nitrogen atom of the acridinium nucleus and the solid phase support as exemplified in FIG. | 12-24-2009 |
20100099077 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION - Chemiluminescent acridinium esters are provided which are fast light emitting and hydrolytically stable. The chemiluminescent acridinium esters are useful labels in assays for detecting or quantifying analytes. | 04-22-2010 |
20120225497 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS - Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity. | 09-06-2012 |
20130065325 | ZWITTERIONIC REAGENTS - Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules. | 03-14-2013 |
20140295575 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS - Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity. | 10-02-2014 |
Patent application number | Description | Published |
20100081764 | AQUEOUS POLYMER DISPERSION AND PROCESS - There is described a multi step process for preparing an aqueous dispersion of heterogeneous polymer particles by mini-emulsion polymerisation, the process comprising the steps of (I) (a) forming a mixture comprising: (i) water; (ii) at least one stabiliser (such as a surfactant and a hydrophobic co-stabiliser); (iii) at least one tackifier (such as polyterpenes, rosin resins and/or hydrocarbon resins); (iv) at least one α,β-ethylenically unsaturated monomer; (b) applying high shear to the mixture from step (a) to form an essentially stable mini-emulsion comprising an aqueous continuous phase and dispersed therein stabilised droplets of average diameter from about 10 to about 1000 nm, (c) polymerising the monomer(s) within the droplets in the presence of a free radical initiator; (d) adding further monomer to the dispersed phase to form a dispersion; then: (II) using the dispersion from step (I) as a seed to form a dispersion of heterogeneous polymer particles in a subsequent emulsion polymerisation. The resultant tackified PSAs may have a core shell structure and are stable under high shear. | 04-01-2010 |
20100093930 | Polymer Composition and Process - There is described a multi step mini-emulsion process for preparing a hybrid acrylic/polyurethane pressure sensitive adhesive (PSA) of very high shear strength, good peel strength and/or also high moisture vapor transmission rate, the process comprising the steps of: a) forming a first aqueous mixture comprising a hydrophilic stabilizer; b) forming separately a second oil mixture comprising: i) at least one vinyl functional polyurethane (optionally prepared from an isocyanate functional monomer; at least one monol and/or at least one α,β-ethylenically unsaturated monomer ii) optionally at least one hydrocarbon polymer (such as polystyrene); and iii) at least one α,β-ethylenically unsaturated monomer (such as (meth)acrylate or acids thereof; and/or iv) option-=ally at least one hydrophobic stabilizer; where components (ii), (iii) and/or (iv) may optionally be the same; c) mixing the aqueous and oil mixtures together to form a pre-(macro) emulsion; d) generating a stable mini-emulsion there-from optionally by applying high shear to form an aqueous continuous phase and stabilized oil droplets of average diameter from about 10 to about 1000 nm, and e) polymerizing the polymer precursor(s) within the droplets, optionally in the presence of a free radical initiator; to obtain a polymer latex. | 04-15-2010 |
Patent application number | Description | Published |
20110142379 | THREE-DIMENSIONAL PLASTIC BAG AND PRODUCTION THEREOF - The present invention relates to an insert for reinforcement of bags made of plastic film, comprising a star-like plastic part having at least three jaws, wherein the insert is adapted for insertion and heat-sealing at a junction inside a three-dimensional bag where at least three plastic films meet, so that each jaw extends in a direction between two films. The invention also relates to a three dimensional bag incorporating such inserts and a method of producing such a bag. | 06-16-2011 |
20110151551 | BIOREACTORS - The present invention relates to improved single-use bioreactors comprising disposable plastic bags for cell cultivation. The invention provides an inflatable bioreactor bag for cell cultivation comprised of a top and a bottom sheet of polymer material that are joined along their edges to form a sealed bag, wherein two opposing edges are formed as clamping edges to allow clamping of the bioreactor bag to a rocker type bioreactor, and wherein the bioreactor bag is provided with a wrinkle preventing structure at each end of the clamping edges. The bag avoids formation of undesired wrinkles or creases which otherwise lead to fatigue of the plastic and eventually fracture. | 06-23-2011 |
20110151552 | BIOREACTORS - The present invention relates to improvements of bioreactor bags for cell cultivation. The invention provides an inflatable bioreactor bag for cell cultivation comprised of a top and a bottom sheet of polymer material that are joined along their edges to form a sealed bag, wherein two opposing edges are formed as clamping edges to allow clamping of the bioreactor bag to a rocker type bioreactor, wherein the top sheet is at least 5% longer than the bottom sheet between the clamping edges. The bioreactor bags provided by the invention avoid formation of undesired wrinkles or creases which otherwise may lead to fatigue of the plastic and eventually fracture. | 06-23-2011 |
Patent application number | Description | Published |
20110042641 | BRANCHED NANOSCALE WIRES - The present invention generally relates to nanotechnology and, in particular, to branched nanoscale wires cases, the branched nanoscale wires may be produced using vapor-phase and/or solution-phase synthesis. Branched nanoscale wires may be grown by depositing nanoparticles onto a nanoscale wire, and segments or “branches” can then be grown from the nanoparticles. The nanoscale wire may be any nanoscale wire, for example, a semiconductor nanoscale wire, a nanoscale wire having a core and a shell. The segments may be of the same, or of different materials, than the nanoscale wire, for example, semiconductor/metal, semiconductor/semiconductor. The junction between the segment and the nanoscale wire, in some cases, is epitaxial. In one embodiment, the nanoparticles are adsorbed onto the nanoscale wire by immobilizing a positively-charged entity, such as polylysine, to the nanoscale wire, and exposing it to the nanoparticles. In another embodiment, nanoparticles are deposited onto a nanoscale wire by etching the nanoscale wire to produce an H-terminated surface, then exposing the surface to a solution comprising a metal ion, which be reduced by the surface to form nanoparticles. Segments or branches can then be grown from the deposited nanoparticles to the branched nanoscale wire. | 02-24-2011 |
20140184196 | NANOSCALE WIRES, NANOSCALE WIRE FET DEVICES, AND NANOTUBE-ELECTRONIC HYBRID DEVICES FOR SENSING AND OTHER APPLICATIONS - The present invention generally relates to nanotechnology, including field effect transistors and other devices used as sensors (for example, for electrophysiological studies), nanotube structures, and applications. Certain aspects of the present invention are generally directed to transistors such as field effect transistors, and other similar devices. In one set of embodiments, a field effect transistor is used where a nanoscale wire, for example, a silicon nanowire, acts as a transistor channel connecting a source electrode to a drain electrode. In some cases, a portion of the transistor channel is exposed to an environment that is to be determined, for example, the interior or cytosol of a cell. A nanotube or other suitable fluidic channel may be extended from the transistor channel into a suitable environment, such as a contained environment within a cell, so that the environment is in electrical communication with the transistor channel via the fluidic channel. In some embodiments, the rest of the transistor channel may be coated, e.g., so that the electrical properties of the transistor channel reflect the electrical behavior of the environment that the fluidic channel is in communication with. Other aspects of the invention are generally directed to methods of making such sensors, methods of using such sensors, kits involving such sensors, or the like. | 07-03-2014 |
Patent application number | Description | Published |
20100067858 | Bandwidth-maintaining multimode optical fibers - The specification describes multimode optical fibers with specific design parameters, i.e., controlled refractive index design ratios and dimensions, which render the optical fibers largely immune to moderately severe bends. The modal structure in the optical fibers is also largely unaffected by bending, thus leaving the optical fiber bandwidth essentially unimpaired. Bend performance results were established by DMD measurements of fibers wound on mandrels vs. measurements of fibers with no severe bends. | 03-18-2010 |
20110243519 | OPTICAL FIBERS WITH TRUNCATED CORES - Optical fiber designs are depicted with a core having an alpha profile inner portion and a steep vertical step between the core and a cladding with no shoulder, referred to herein as a truncated core. A further aspect of this invention can include a trench between the truncated core and cladding. In this embodiment, the core performs as not only as the primary light guiding structure, but now also functions essentially the same as that of a trench structure. Thus, what was formally a trench can now be much less negative or even positive. | 10-06-2011 |
20120183267 | BANDWIDTH-MAINTAINING MULTIMODE OPTICAL FIBERS - The specification describes multimode optical fibers with specific design parameters, i.e., controlled refractive index design ratios and dimensions, which render the optical fibers largely immune to moderately severe bends. The modal structure in the optical fibers is also largely unaffected by bending, thus leaving the optical fiber bandwidth essentially unimpaired. Bend performance results were established by DMD measurements of fibers wound on mandrels vs. measurements of fibers with no severe bends. Additional embodiments of the present invention describe an improved optical link when the inventive multimode fiber is connected to standard or conventional multimode fibers. | 07-19-2012 |
20140125971 | DEVICE AND METHOD TO MEASURE THE DMD AND OTHER PARAMETERS OF A MULTICORE OPTICAL FIBER - Apparatus and method of simultaneously measuring a parameter of a plurality of cores in at least one optical fiber. An input tester at a first end of the test fiber has a plurality of tester signal inputs with a geometry substantially matching at least a portion of the core geometry of the fiber. At least one test input signal source coupled to the plurality of tester signal inputs. A signal measuring device is alignable at a second end of the fiber to measure the output of the test input signal. The input tester may include a tapered multicore coupler or a laser having a shield with apertures disposable between the laser and the fiber. In the latter case, a lens may be disposed between the shield and the fiber to project light from the laser that passes through the apertures onto the end of the fiber. | 05-08-2014 |
20140270670 | Bandwidth-Maintaining Multimode Optical Fibers - The specification describes multimode optical fibers with specific design parameters, i.e., controlled refractive index design ratios and dimensions, which render the optical fibers largely immune to moderately severe bends. The modal structure in the optical fibers is also largely unaffected by bending, thus leaving the optical fiber bandwidth essentially unimpaired. Bend performance results were established by DMD measurements of fibers wound on mandrels vs. measurements of fibers with no severe bends. | 09-18-2014 |
Patent application number | Description | Published |
20080280832 | Novel Fsh Glycosylation Variant D3n - FSH mutant with increased glycosylation and longer half-life is described. The use of this FSH mutant for inducing folliculogenesis in human patients is also described. | 11-13-2008 |
20090018070 | Fsh Mutants - FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described. | 01-15-2009 |
20090093462 | 3-Arylamino pyridine derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. | 04-09-2009 |
20090130712 | Compositions and Methods of Producing Hybrid Antigen Binding Molecules and Uses Thereof - This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy. | 05-21-2009 |
20090306069 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES - The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. | 12-10-2009 |
20110224192 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 09-15-2011 |
20110294801 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS - Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases. | 12-01-2011 |
20120295889 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 11-22-2012 |
20140051686 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 02-20-2014 |
Patent application number | Description | Published |
20090263347 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. In some cases, the methods entail treating the co-polymer with pyro-glutamate aminopeptidase to cleave N-terminal pyro-glutamate residues. | 10-22-2009 |
20100331266 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 12-30-2010 |
Patent application number | Description | Published |
20130095515 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 04-18-2013 |
20140065652 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 03-06-2014 |
20150376334 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 12-31-2015 |
20160069892 | ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS - Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard. | 03-10-2016 |
Patent application number | Description | Published |
20090226395 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential - The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues. | 09-10-2009 |
20100151037 | METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND - The present application relates to a method for preparing nanoparticles containing a poorly water-soluble pharmaceutically acceptable compound and compositions containing such nanoparticulates. | 06-17-2010 |
20110112180 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS - The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds. | 05-12-2011 |
20120252763 | NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS - The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds. | 10-04-2012 |
20130150437 | NAPHTHOQUINONES FOR DISEASE THERAPIES - The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases. | 06-13-2013 |
20150018410 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS - The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds. | 01-15-2015 |
Patent application number | Description | Published |
20080242606 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 10-02-2008 |
20100211066 | Use of IMP3 as a Prognostic Marker for Cancer - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 08-19-2010 |
20110034398 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 02-10-2011 |
20130197514 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 08-01-2013 |
20130252888 | USE OF IMP3 AS A PROGNOSTIC MARKER FOR CANCER - Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided. | 09-26-2013 |